Welcome to Best Pharmacy at Havmeds! Go shopping!

Product ID: 969051

Reminder: The pictures displayed on this site maybe different from the actual product,their maybe a delay in updating the recent picture if their a newly launched packaging from the manufacturer

Tagrisso 80mg Tablet

Tagrisso 80mg Tablet is for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive (NSCLC) which have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy, as determined by an approved test.



Trade name
Tagrisso 80mg Tablet
Astra Zeneca
Main ingreadient
Not Available
Please discuss the logistics method with the customer service executive on customer service whatsapp/wechat/zalo/viber account
Please follow the doctor’s advice when taking medicines. The mall only guarantees the quality of the medicines and does not provide medical advice.

Authenticity guarantee

India Direct Mail

Privacy packaging

Pharmacy Direct


Tagrisso 80mg Tablet (Osimertinib)

Tagrisso 80mg Tablet is a drug that is available only with a doctor's prescription and is used to treat adults who have non-small cell lung cancer (NSCLC) and have one or more faulty genes that code for epidermal growth factor receptor (EGFR):

  • to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery, 

  • or \ as your first treatment when your lung cancer has spread to other parts of the body (metastatic), 

  • or \ when your lung cancer has spread to other parts of the body (metastatic) and you have had previous treatment with an EGFR Tyrosine Kinase Inhibitor (TKI) medicine that did not work or is no longer working

  • In order to determine whether or not TAGRISSO is the appropriate treatment for you, your healthcare professional will conduct a test.

How does TAGRISSO work?

TAGRISSO 80mg tablet is effective against cancers that have been found to be positive for specific types of EGFR mutations. TAGRISSO is designed to zero in on and inhibit the mutant EGFR that is present in cancer cells.

It is unknown at this time if TAGRISSO is both safe and effective when administered to youngsters.

TAGRISSO users are most likely to have the following side effects:

  • low levels of white blood cells in the blood

  • platelet levels that are too low

  • diarrhea

  • low levels of red blood cells in the blood (anemia)

  • rash

  • muscle, bone, or joint pain

  • alterations in the appearance of your nails, including redness, tenderness, soreness, inflammation, brittleness, detachment from the nailbed, and shedding of the nail.

  • dry skin

  • ulcers of the mouth

  • tiredness

  • cough

Before you start taking TAGRISSO 80mg tablets, you should discuss all of your medical conditions with your healthcare professional. This is especially important if you have any of the following conditions:

  • have issues with their lungs or breathing

  • have issues with their hearts, one of which is a disease known as long QTc syndrome.

  • you may be experiencing issues with your electrolytes, such as sodium, potassium, calcium, or magnesium.

  • have a family history of eye conditions

  • pregnant or intend to become pregnant in the near future. TAGRISSO poses a risk to the health of your unborn child. If you become pregnant while taking TAGRISSO or if you have any reason to believe that you may be pregnant, you should contact your healthcare provider as soon as possible.

Consult your doctor

Before beginning therapy with TAGRISSO 80mg tablets, all females who are of childbearing age and who are capable of getting pregnant should get a pregnancy test. You should always use a reliable method of birth control while you are being treated with TAGRISSO and for at least six weeks after the last dose of TAGRISSO that you take.

During treatment with TAGRISSO and for the next four months after the last dosage of TAGRISSO, males with female partners who are capable of becoming pregnant should use an effective method of birth control, whether they are breastfeeding or plan to breastfeed their children. 

There is no evidence to suggest that TAGRISSO makes its way into breast milk. Do not breastfeed while you are receiving TAGRISSO medication and for at least 2 weeks after your last dose of TAGRISSO has been administered. Have a conversation with your primary care physician about the optimal method of feeding your infant at this stage.

Tell your doctor about any and all of the medications you take, whether they are prescribed to you or purchased over the counter, as well as any vitamins or herbal supplements you might be taking. Notify your healthcare professional, in particular, if you take any medications for your heart or blood pressure.

Osimertinib is taken once a day in an 80 mg tablet form. Tagrisso is a food supplement that can be taken with or without food.If you miss a dose of Osimertinib, skip the missed dose and continue with your regular regimen.
Related Products
Copyright 2023 havmeds.com. All Rights Reserved
Call Us